WordNet
- an impairment of health or a condition of abnormal functioning
- caused by or altered by or manifesting disease or pathology; "diseased tonsils"; "a morbid growth"; "pathologic tissue"; "pathological bodily processes" (同)morbid, pathologic, pathological
- of or relating to or involved in hematology (同)haematological, hematological
PrepTutorEJDIC
- (体の)『病気』,疾患 / (精神・道徳などの)病気,病弊
- 女性の話術芸人 =diseur
- 病気にかかった / 病的な,不健全な(morbid)
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 銅欠乏性ミエロニューロパチー copper deficiency myeloneuropathy
- 2. 全身性硬化症（強皮症）における間質性肺炎の予後および治療 prognosis and treatment of interstitial lung disease in systemic sclerosis scleroderma
- 3. 肝移植の非免疫性合併症 nonimmunologic complications of liver transplantation
- 4. 急性骨髄性白血病における寛解基準および残存病変のモニタリング remission criteria in acute myeloid leukemia and monitoring for residual disease
- 5. 鎌状赤血球症における肝臓の症状 hepatic manifestations of sickle cell disease
English Journal
- Sex chromosome loss may represent a disease-associated clonal population in chronic lymphocytic leukemia.
- Chapiro E, Antony-Debre I, Marchay N, Parizot C, Lesty C, Cung HA, Mathis S, Grelier A, Maloum K, Choquet S, Azgui Z, Uzunov M, Leblond V, Merle-Beral H, Sutton L, Davi F, Nguyen-Khac F.Author information Service d'Hématologie Biologique, Hôpital Pitié-Salpêtrière, Paris, France; INSERM U872, Centre de Recherche des Cordeliers, Paris, 6, France; UPMC, Paris, 6, France.AbstractWhether sex chromosome loss (SCL) is an age-related phenomenon or a cytogenetic marker of hematological disease is unclear. To address this issue in chronic lymphocytic leukemia (CLL), we investigated 20 cases with X or Y chromosome loss detected by conventional cytogenetics (CC). The frequency of SCL was low in CLL (2.3%). It was the sole abnormality, as detected by CC, in 10/20 (50%) patients. Fluorescence in situ hybridization (FISH) analyses confirmed SCL in all patients tested, present in 5-88% of cells (median: 68%). Deletions of 13q were observed by FISH in 16/20 (80%) patients. Compared with CLL without SCL, SCL was significantly associated with 13q deletion, especially when bi-allelic (P = 0.04). Co-hybridization analyses showed that SCL could be a concomitant, primary or secondary change, or be present in an independent clone. FISH analyses were performed on blood sub-populations isolated by Ficoll or flow cytometry. Comparing mononuclear cells (including CLL cells) and polynuclear cells separated by Ficoll, a maximum of 2% of polynuclear cells were found with SCL, whereas mononuclear cells exhibited a significantly higher loss frequency (range: 6-87%) (P = 0.03). Comparing B-cells (including CLL cells) and T-cells sorted by flow cytometry, the proportion of B-CD19+ cells with SCL was significantly higher (range: 88-96%) than that observed in T-CD3+ cells (range: 2-6%) (P = 0.008). We conclude that SCL has to be considered as a clonal aberration in CLL that may participate in the oncogenic process. © 2013 Wiley Periodicals, Inc.
- Genes, chromosomes & cancer.Genes Chromosomes Cancer.2014 Mar;53(3):240-7. doi: 10.1002/gcc.22134. Epub 2013 Nov 30.
- Whether sex chromosome loss (SCL) is an age-related phenomenon or a cytogenetic marker of hematological disease is unclear. To address this issue in chronic lymphocytic leukemia (CLL), we investigated 20 cases with X or Y chromosome loss detected by conventional cytogenetics (CC). The frequency of S
- PMID 24424752
- Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
- Kiesewetter B, Mayerhoefer ME, Lukas J, Zielinski CC, Müllauer L, Raderer M.Author information Clinical Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, 1090, Austria.AbstractRecently, the combination of rituximab and bendamustine (R-Benda) has been defined as highly active in patients with follicular lymphomas, but little is known about the efficacy of R-Benda in mucosa-associated lymphoid tissue (MALT) lymphoma. In a retrospective analysis, we have defined 14 patients with MALT lymphoma undergoing therapy with R-Benda. Seven patients were female and seven male (aged 44-88 years), and all had relapsed extragastric MALT lymphoma. R-Benda was given at first relapse in ten patients, while four patients had more than two prior forms of therapy. Bendamustine was given at a dose of 90 mg/m(2) on days 2 and 3 in ten patients and at 70 mg/m(2) in three patients, while all received 375 mg/m(2) rituximab on day 1. Ten patients received six courses of therapy, while two patients discontinued therapy after three, and one after four courses for personal reasons, while one patient had progressive disease after four courses. Tolerance of therapy was excellent, and all except one patient responded. Ten patients achieved a complete remission (CR) (71 %), three a partial remission (21 %), while one patient progressed. Toxicities were mild and mainly hematological but did not result in relevant delays or the necessity for dose reductions. After a median follow-up of 23 months (range, 4-42+), 13 patients are alive and one patient has relapsed 23 months after initial CR. Our data suggest high activity and good tolerance of R-Benda in patients with relapsed MALT lymphoma despite intensive pretreatment in some patients. In view of this, prospective studies are warranted.
- Annals of hematology.Ann Hematol.2014 Feb;93(2):249-53. doi: 10.1007/s00277-013-1865-3. Epub 2013 Aug 8.
- Recently, the combination of rituximab and bendamustine (R-Benda) has been defined as highly active in patients with follicular lymphomas, but little is known about the efficacy of R-Benda in mucosa-associated lymphoid tissue (MALT) lymphoma. In a retrospective analysis, we have defined 14 patients
- PMID 23925930
- A fast and simple approach for the simultaneous detection of hematopoietic chimerism, NPM1, and FLT3-ITD mutations after allogeneic stem cell transplantation.
- Waterhouse M, Bertz H, Finke J.Author information Department of Hematology and Oncology, University Medical Center Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany, miguel.waterhouse@uniklinik-freiburg.de.AbstractHematopoietic chimerism can be used as a tool for patient management after allogeneic hematopoietic stem cell transplantation (HSCT). An increase in the proportion of recipient cells after transplantation is strongly associated with relapse in chronic myeloid leukemia. However, in acute myeloid leukemia (AML) the significance of increasing mixed chimerism (MC) as a predictive marker for relapse is less clear. Several mutations frequently found in AML have been employed for minimal residual disease detection and relapse prediction. Therefore, a combined analysis of hematopoietic chimerism and of the molecular aberrations found in AML could be used to improve MC characterization. We developed a multiplex PCR for use in the simultaneous detection of hematopoietic chimerism and mutations in nucleophosmin (NPM1) and fms-like tyrosine kinase-3 internal tandem duplication (FLT3-ITD). A total of 303 samples from 20 AML patients were analyzed after HSCT. The microsatellite markers used for hematopoietic chimerism detection were D1S80, D7S1517, D4S2366, THO1, and SE33. A total of 149 samples from 18 patients showed MC with a mean detection time of 9.7 months. From the 18 patients with MC, in 6 of the patients, no FLT3-ITD or NPM1 mutation was found at any time point tested, and these patients remained in complete hematological remission. In 12 patients with MC, FLT3-ITD and NPM1 mutations were found, and these patients showed signs of hematological relapse. Our combined analysis of NPM1/FLT3-ITD mutations and hematopoietic chimerism improved the characterization of patients with MC after HSCT. The present approach may be further expanded by combining additional mutations found in AML with hematopoietic chimerism detection.
- Annals of hematology.Ann Hematol.2014 Feb;93(2):293-8. doi: 10.1007/s00277-013-1858-2. Epub 2013 Aug 2.
- Hematopoietic chimerism can be used as a tool for patient management after allogeneic hematopoietic stem cell transplantation (HSCT). An increase in the proportion of recipient cells after transplantation is strongly associated with relapse in chronic myeloid leukemia. However, in acute myeloid leuk
- PMID 23907410
Japanese Journal
- がんの最新治療 各論(5)多発性骨髄腫
- 今井 陽一
- 東京女子医科大学雑誌 83(3), 160-167, 2013-06-25
- 形質細胞由来の造血器腫瘍である多発性骨髄腫は血清・尿中の単クローン性免疫グロブリンの産生を特徴とする。貧血などの造血障害、溶骨病変、腎機能障害、易感染性などの様々な臨床症状を伴いADLの低下を伴う場合がみられる難治・再発性の悪性腫瘍である。治療としては従来の化学療法であるMP (メルファラン・プレドニン)療法では完全寛解を得られることは困難で十分な生存期間を得られなかった。近年になって大量化学療法 …
- NAID 110009605129
- 肉眼的血尿, 前立腺生検後の皮下出血を契機に診断された後天性血友病の1例
- 木村 博子,植垣 正幸,青山 輝義,三好 隆史,永井 謙一,橋村 孝幸
- 泌尿器科紀要 59(5), 305-308, 2013-05-00
- … Acquired hemophilia is a rare disease that can result in life threatening bleeding associated with coagulation factor VIII inhibitors. … Further hematological evaluation showed the presence of coagulation factor VIII inhibitors, which led to the diagnosis of acquired hemophilia. …
- NAID 120005245082
- 急性リンパ性白血病に合併した腸管嚢胞様気腫症の1例 : 血液疾患に合併する同症についての文献的考察を加えて
- 塩崎 宏子,岡村 隆光,田嶋 強,石山 みどり,吉永 健太郎,志関 雅幸,森 直樹,寺村 正尚,泉二 登志子
- 東京女子医科大学雑誌 83(E2), E638-E642, 2013-03-31
- 急性リンパ性白血病に対する化学療法中に腸管嚢胞様気腫症(PCI)を合併した症例を経験したので、成人血液疾患に合併するPCIについて文献的考察を加えて報告した。症例は16歳男性。急性リンパ性白血病と診断され、化学療法により完全寛解を得たが、地固め療法中に腹痛と下痢を認め、腹部単純X線と腹部CTによりPCIと診断された。絶食、輸液、酸素吸入などの保存的治療によって改善した。当科において最初のPCI症例 …
- NAID 110009575079
Related Links
- would like to inform you that I do not have any hematological disease .... Hi Thanks for your query. All your reports are fine. Hemoglobin is maintained throughout so I would not bother about the MCV or MCH. The normal I do ...
- View Hematological Disease's business profile and see work history, affiliations and more. ... Share This Profile Share this profile on Facebook. Link to this profile on LinkedIn. Tweet this profile on Twitter. Email a link to this profile.
Related Pictures
★リンクテーブル★
| リンク元 | 「blood disease」「血液病」「hematologic disorder」「haematological disease」 |
| 関連記事 | 「disease」「hematological」「hematologic」 |
「blood disease」
- 関
- blood disorder、blood dyscrasia、haematological disease、haematological disorder、hematologic disease、hematologic disorder、hematological disease、hematological disorder、hemopathy
「血液病」
「hematologic disorder」
「haematological disease」
「disease」
- n.
- 疾患：illnessより厳密な概念。「ある臓器に明確な障害が確認され、それによって症状が出ているとはっきり説明できる場合」 (PSY.9)
- 特定の原因、病態生理、症状、経過、予後、病理組織所見が全てそろった場合 (PSY.9)
- something that is very wrong with people's attitudes, way of life or with society.
- 注意
「hematological」
- 血液学的な、血液学の
- 関
- haematologic、haematological、haematologically、haematology、hematol、hematologic、hematologically、hematology
「hematologic」
- 血液学的な